CMS5 tumor cells are more sensitive to the MMC treatment, as evidenced by a higher proportion of calreticulin and HMGB1-positive cells, compared to E.G7 tumor cells (Figure 2), which are more likely to undergo immunogenic cell death. This evidence concerns the gene CALR and neoplasm.